

Hajnalka Andrikovics

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6400226/publications.pdf>

Version: 2024-02-01

8
papers

223
citations

1684188

5
h-index

1474206

9
g-index

10
all docs

10
docs citations

10
times ranked

447
citing authors

#	ARTICLE	IF	CITATIONS
1	Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations. <i>Haematologica</i> , 2014, 99, 1184-1190.	3.5	83
2	Molecular diagnostics of myeloproliferative neoplasms. <i>European Journal of Haematology</i> , 2015, 95, 270-279.	2.2	67
3	Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1028-1035.	1.3	30
4	Co-occurrence of Myeloproliferative Neoplasms and Solid Tumors Is Attributed to a Synergism Between Cytoreductive Therapy and the Common <i>TERT</i> Polymorphism rs2736100. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 98-104.	2.5	21
5	<i>HFE</i> C282Y Mutation as a Genetic Modifier Influencing Disease Susceptibility for Chronic Myeloproliferative Disease. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 929-934.	2.5	11
6	Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia. <i>PLoS ONE</i> , 2021, 16, e0253386.	2.5	5
7	The adverse effect of FOPNL genomic variant is reversed by bortezomib-based treatment protocols in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2018, 59, 710-716.	1.3	1
8	Investigation of <i>TGFB1</i> 1347C>T variant as a biomarker after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 215-223.	2.4	1